Avamys (Fluticasone Furoate) Pediatric Dosing
For children aged 2-11 years, use 1-2 sprays (27.5-55 mcg) per nostril once daily; for children over 11 years, use 2 sprays (55 mcg) per nostril once daily. 1
Age-Specific Dosing Algorithm
Children 2-11 Years Old
- Starting dose: 1 spray per nostril once daily (27.5 mcg total daily dose)
- Maximum dose: 2 sprays per nostril once daily (55 mcg total daily dose)
- Timing: Administer once daily, preferably in the morning
Children Over 11 Years (Adolescents and Adults)
- Standard dose: 2 sprays per nostril once daily (55 mcg total daily dose)
- Timing: Once daily administration
Clinical Context from Guidelines
The 2015 American Academy of Otolaryngology-Head and Neck Surgery clinical practice guideline clearly identifies fluticasone furoate (marketed as Veramyst/Avamys) as approved for children as young as 2 years of age for both seasonal and perennial allergic rhinitis 1. Each spray delivers 27.5 mcg of fluticasone furoate as a suspension formulation.
Important Safety Considerations
Growth monitoring is essential in prepubescent children. A 2014 study demonstrated that continuous use of fluticasone furoate nasal spray 110 mcg once daily (equivalent to 2 sprays per nostril) over 52 weeks resulted in a small but statistically significant reduction in growth velocity compared to placebo (mean difference -0.27 cm/year) in children aged 5 to <8.5 years 2. While this reduction is modest, clinicians must balance this against clinical benefit and monitor growth parameters regularly in children on long-term therapy.
Common Adverse Effects
The most frequently reported side effects in pediatric patients include 1:
- Epistaxis (nosebleeds)
- Headache
- Pharyngolaryngeal pain
- Nasal ulceration
- Back pain
- Pyrexia
- Cough
Contraindications
- History of hypersensitivity to fluticasone furoate or any component of the formulation 1
Efficacy Evidence in Children
Multiple studies support the effectiveness of fluticasone furoate in pediatric populations. A 2009 study in children aged 6-11 years with seasonal allergic rhinitis demonstrated that the 110 mcg once-daily dose (2 sprays per nostril) significantly improved total nasal symptom scores compared to placebo over 2 weeks 3. The 55 mcg dose showed numerical but not statistically significant improvement.
For perennial allergic rhinitis, a 12-week study in children aged 2-11 years showed that the 55 mcg once-daily dose demonstrated significant improvement (p=0.003) compared to placebo, though the 110 mcg dose did not reach statistical significance in the primary analysis 4.
Clinical Pitfalls to Avoid
- Do not exceed recommended doses: The maximum pediatric dose is 2 sprays per nostril once daily (55 mcg total)
- Monitor growth in prepubescent children: Use stadiometry for objective measurement during long-term therapy
- Ensure proper administration technique: The medication must be administered as a nasal spray using the proper device; the drug label evidence provided appears to reference a different product (lice treatment) and should be disregarded 5
- Consider dose adjustment: Start with the lower dose (1 spray per nostril) in younger children (2-11 years) and increase only if needed for symptom control
Position Among Treatment Options
Intranasal corticosteroids, including fluticasone furoate, represent first-line therapy for allergic rhinitis across all age groups according to the 2017 Joint Task Force guidelines 6. They are more effective than oral antihistamines and leukotriene receptor antagonists for comprehensive symptom control, particularly for nasal congestion.